Medications

Despite widespread attention for medications like Ozempic, Wegovy, and Mounjaro, a new Yale study reveals only 3% of eligible adults are actually getting these weight loss drugs. This highlights significant barriers and disparities in who can access these powerful treatments.

A first-of-its-kind study directly comparing Zepbound and Wegovy for weight loss has found that Zepbound led to significantly greater weight reduction, with participants losing an average of 50 pounds compared to Wegovy’s 33 pounds.

The FDA cautions against using unapproved or compounded versions of GLP-1 drugs for weight loss, citing significant safety concerns due to the lack of regulatory oversight and potential for adverse events, including dosing errors and counterfeit products. Patients are strongly advised to obtain prescriptions from licensed pharmacies and consult their healthcare providers for safe medication practices.

In a recent discussion, Dr. Janese Laster highlighted the importance of personalized care in weight loss treatment, emphasizing that both lifestyle changes and appropriate medication play crucial roles in achieving sustainable weight loss. She also noted the significant cost differences between older oral medications and newer injectables, underscoring the need for patients to consult qualified specialists for effective management.

With the rise of medications such as Wegovy and Zepbound, some might think we have found the answer to rising rates of obesity. But scientists and doctors say there’s still more to come when it comes to perfecting weight loss drugs and treating obesity. Here’s what scientific breakthroughs doctors are looking forward to seeing in the field. 

Break through your weight loss plateau with the help of effective supplements. Discover the science behind it!